Literature DB >> 9462248

Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins.

S Kitchen1, F E Preston.   

Abstract

BACKGROUND: A number of instruments have been developed for determination of prothrombin time (PT) and International Normalised Ratio (INR) at locations not limited to central laboratories. AIM: To evaluate one such portable instrument, the Thrombolytic Assessment System (TAS), which can be used in a near-patient setting.
METHODS: Samples from 20 normal subjects and 48 patients treated with warfarin for venous thromboembolic disease were studied. The warfarin group was divided into: initiation phase (n = 10), combined warfarin and heparin (n = 10), stabilised therapy (n = 20), and over anticoagulated patients (n = 8). PTs and INRs were determined in each group using three conventional thromboplastins (Diagen Activated, Manchester Reagent, and Instrumentation Laboratory) and two TAS techniques (whole blood or plasma). An independent International Sensitivity Index (ISI) calibration of the TAS system was performed.
RESULTS: Calculated ISIs for the TAS were 1.028 and 0.984 for plasma and whole blood analysis, respectively, compared with manufacturer's values of 0.98 and 0.97. INR results with TAS (whole blood) were 11% less than those obtained with Diagen Activated (p < 0.01) and 16% less than those obtained with Instrumentation Laboratory (p < 0.001) when manufacturers' mean normal PT and ISI were used for TAS INRs. TAS (whole blood) results were similar to TAS plasma or Manchester Reagent results. The use of a locally determined mean normal prothrombin time (MNPT) improved agreement between TAS and the other reagents, abolishing the significant difference between INRs determined with TAS (whole blood) and Diagen Activated techniques.
CONCLUSION: The TAS system can be used with whole blood or plasma and produces similar INRs to those obtained with Diagen Activated or Manchester Reagent using manufacturer's ISI and a locally determined MNPT. Results were lower with TAS or Manchester Reagent compared with those obtained with Instrumentation Laboratory thromboplastin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462248      PMCID: PMC500323          DOI: 10.1136/jcp.50.11.951

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis.

Authors:  B J Oberhardt; S C Dermott; M Taylor; Z Y Alkadi; A F Abruzzini; N J Gresalfi
Journal:  Clin Chem       Date:  1991-04       Impact factor: 8.327

2.  Thromboplastin--sensitivity, precision and other characteristics.

Authors:  K W Denson
Journal:  Clin Lab Haematol       Date:  1988

Review 3.  Confusion over the therapeutic range for monitoring oral anticoagulant therapy in North America.

Authors:  J Hirsh; M Levine
Journal:  Thromb Haemost       Date:  1988-04-08       Impact factor: 5.249

4.  Calibration of BCT/441, the ICSH reference preparation for thromboplastin.

Authors:  J M Thomson; K V Darby; L Poller
Journal:  Thromb Haemost       Date:  1986-06-30       Impact factor: 5.249

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Two recombinant tissue factor reagents compared to conventional thromboplastins for determination of international normalised ratio: a thirty-three-laboratory collaborative study. The Steering Committee of the UK National External Quality Assessment Scheme for Blood Coagulation.

Authors:  S Kitchen; I Jennings; T A Woods; I D Walker; F E Preston
Journal:  Thromb Haemost       Date:  1996-09       Impact factor: 5.249

7.  Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control.

Authors:  E A Loeliger; A M van den Besselaar; S M Lewis
Journal:  Thromb Haemost       Date:  1985-02-18       Impact factor: 5.249

8.  Imprecision of prothrombin time monitoring of oral anticoagulation. A survey of hospital laboratories.

Authors:  J E Ansell
Journal:  Am J Clin Pathol       Date:  1992-08       Impact factor: 2.493

9.  Outpatient use of a portable international normalized ratio/prothrombin time monitor.

Authors:  R H White; D M Becker; M G Gunther-Maher
Journal:  South Med J       Date:  1994-02       Impact factor: 0.954

10.  Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer.

Authors:  V L Rose; S C Dermott; B F Murray; M M McIver; K A High; B J Oberhardt
Journal:  Arch Pathol Lab Med       Date:  1993-06       Impact factor: 5.534

View more
  3 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Accuracy, precision, and quality control for point-of-care testing of oral anticoagulation.

Authors:  A M van den Besselaar
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

Review 3.  Clinical utilization of the international normalized ratio (INR).

Authors:  R S Riley; D Rowe; L M Fisher
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.